세계의 면역형광 어세이 시장 평가 : 제품별, 유형별, 용도별, 최종 사용자별, 지역별, 기회, 예측(2018-2032년)

Global immunofluorescence assays market is projected to witness a CAGR of 6.39% during the forecast period 2025-2032, growing from USD 3.93 billion in 2024 to USD 6.44 billion in 2032. The growth of the market is supported by the rapid expansion of the biotechnology industry, the increasing burden on the healthcare sector, and rising investments in research and development activities.

Additionally, emerging applications of immunofluorescence assays in a wide range of domains bolstered the market's demand. Immunofluorescence assays can be deployed on tissues or cells to determine the presence or absence of various biological compounds such as proteins and carbohydrates. The technique is also utilized in molecular biology for visualization of cytoskeletons. Such applications significantly support the market's growth in different regions across the globe.

The growing threat of autoimmune diseases is one of the key global immunofluorescence assays market trends. The immunochemical technique allows the localization and detection of a wide range of antigens in various tissue types for cell preparation. Immunofluorescence assays are essential for diagnosing autoimmune diseases as they are able to recognize the autoantibodies. The rising incidences of different autoimmune diseases, including lupus, multiple sclerosis, and rheumatoid arthritis, are propelling the requirement for immunofluorescence assays. As per the estimates published by the Centers for Disease Control and Prevention in May 2024, approximately 204,000 individuals in the United States are suffering from systemic lupus erythematosus (SLE). Early detection of biomarkers can allow the delivery of better and safer treatments with limited side effects along with the efficient utilization of drugs as they are tailored to the unique clinical and immunological features of the patients. Thus, ensuring the judicious usage of healthcare services and resources and cost efficiency.

The growing efforts of leading market players and research organizations to bolster the availability of sophisticated technologies and novel instruments are also expected to provide lucrative growth opportunities to the market. Innovations in imaging systems and fluorescent dyes coupled with automation of diagnostic systems are increasing the specificity and sensitivity of indirect fluorescent antibody techniques.

Increasing Prevalence of Chronic Diseases Boosts Market Demand

The growing threat of chronic diseases and disorders is one of the major drivers of the immunofluorescence assay market. The data published by the World Health Federation in May 2023 stated that the deaths from cardiovascular disease (CVD) have surged by 60% since 1990. The data further mentioned that CVD is a leading cause of death worldwide, with four in five CVD deaths occurring in low- and middle-income countries (LMICs).

Immunofluorescence assays play a crucial role in diagnosing and detecting a wide range of infectious, autoimmune, and chronic diseases. In cancer diagnostics, immunofluorescence assays allow the detection of tumor-specific antigens in a time-efficient manner, enabling early diagnosis and guiding healthcare professionals through personalized treatment approaches. Additionally, the growing threat of infectious diseases, including HIV and tuberculosis, is also bolstering the requirement for immunofluorescence assays for accurate and rapid pathogen detection. They also allow the identification of various drug-resistant and emerging disease strains. As the threat of such conditions rises, the demand for technological solutions that provide accurate results and timely diagnosis is increasing, as early detection and intervention are essential for effectively treating and managing various chronic conditions.

Rising Research Activities Support Market Expansion

Increasing investments in biomedical research, along with increasing studies for evaluating molecular and cellular mechanisms, validating therapeutic targets, and comprehending disease pathways, are propelling the market's expansion. An increasing number of clinical trials also support the market's expansion. For instance, Dartmouth Hitchcock Medical Center is conducting an observational study to evaluate the association between bone and tissue perfusion in efforts to develop indocyanine green fluorescence imaging as a diagnostic solution for quantitively guiding operative debridement. The study population includes patients with open fractures, and the secondary outcome measure of the study includes surgical site infection. The study is expected to conclude in January 2025. Moreover, the rising investments by different government organizations and research institutions to strengthen their country's biomedical research sector are also positively influencing the expansion of the immunofluorescence assay market. The rising emphasis on biomedical research can be attributed to evolving healthcare requirements, increasing global health challenges, and rising awareness among the general population. The histochemical staining technique is utilized to demonstrate the absence or presence of antibodies that are bound to antigens present in circulating body fluids or tissues. Thus, this will bolster the demand for immunofluorescence assays across research and academic institutions and positively influence the growth of the immunofluorescence assays market.

Pharmaceutical and Biotechnology Companies Account for Significant Share of the Market

The growing burden of different diseases, coupled with increasing investments in research and development activities in pharmaceutical and biotechnology industries to support the development of novel therapies and advanced diagnostic solutions, is propelling the growth of the global immunofluorescence assay market. Biotechnology and pharmaceutical companies deploy immunofluorescence assays in different drug discovery processes as well as for developing various diagnostic solutions. They are also widely used for validating and identifying therapeutic targets, monitoring biomarkers' expression, and assessing drug efficacy. Thus, making them crucial for developing immunological and oncological drugs, among others. The rising investments in research and development activities also provide lucrative growth opportunities for the market. As per the European Federation of Pharmaceutical Industries and Associations (EFPIA), approximately USD 52,079 million was invested in research and development by the pharmaceutical industry in Europe in 2023. Moreover, the increasing emphasis on personalized medicines is driving the adoption of advanced immunofluorescence assays by both pharmaceutical and biotechnology companies to enable the identification of patient-specific biomarkers to support the development of targeted treatments and improve clinical outcomes.

North America Holds Major Market Share

The presence of advanced technologies, increasing investments towards enhancing the healthcare sector, and the strong presence of leading research institutions and market players are some of the major factors supporting the growth of the North American immunofluorescence assay market. The increasing efforts of various government agencies in the region to boost awareness about various infectious diseases and curb their spreading is another major factor augmenting the requirement for immunofluorescence assays in the region. Additionally, the prevalence of chronic diseases such as cancer in countries such as the United States is also augmenting the market's demand. As per the estimates of the American Cancer Society, around 2,001,140 new cases of cancer were reported in the United States in 2024. Immunofluorescence provides valuable prognostic information by identifying cancer cells and showing where certain proteins are localized and expressed in the cancer cells along with other nonbiological and biological substances. Furthermore, the rising investments towards research activities and provision of funding opportunities by the governments in the region to foster research and innovation in biological and pharmaceutical domains are also expected to influence the market's expansion in North America positively.

Future Market Scenario (2025-2032F)

As per the global immunofluorescence assays market analysis, the market is expected to observe significant growth over the forecast period due to the growing burden of chronic and infectious diseases, increasing investments in the healthcare industry, and technological advancements. According to the estimates of WHO, approximately 35 million new cases of cancer are expected to be diagnosed in 2050. Technological advancements, including the integration of artificial intelligence with immunofluorescence imaging along with the increasing efforts to boost the development of automated platforms, are also expected to play a crucial role in shaping the market.

Additionally, the continuous efforts of the key players of the market to expand their product portfolios, coupled with their increasing focus on research and development, is expected to bolster the availability of user-friendly and economically efficient solutions in the coming years, increasing the accessibility of advanced diagnostic tools and supporting the market's expansion. Furthermore, the increasing efforts of various governments to improve their disease surveillance capabilities and strengthen their research sector is also expected to propel the demand for the immunofluorescence assays market.

Key Players Landscape and Outlook

The growth of the market is bolstered by increasing investments by leading pharmaceutical and biotechnology companies towards collaborations and partnerships to expand their global presence and ensure the availability of novel products and technologies. For instance, in January 2023, Akoya Biosciences, Inc. and Agilent Technologies, Inc. announced a partnership for developing multiplex-immunohistochemistry diagnostic solutions for analyzing tissues and commercializing workflow solutions for multiplex assays. By combining Akoya's imaging platform, PhenoImager HT, and Agilent's autostaining instrument, Dako Omnis, for immunofluorescent assays and multiplex chromogenic immunohistochemistry, the companies created a singular end-to-end commercial workflow that includes imaging, analysis, and staining. These assay solutions are allowing medical professionals and researchers to translate their discoveries into clinical solutions.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Immunofluorescence Assays Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Products
    • 4.2.1.1. Antibodies
      • 4.2.1.1.1. Primary Antibodies
      • 4.2.1.1.2. Secondary Antibodies
    • 4.2.1.2. Kits and Reagents
      • 4.2.1.2.1. Stains and Dyes
      • 4.2.1.2.2. Media and Sera
      • 4.2.1.2.3. Buffers and Solvents
      • 4.2.1.2.4. Probes
      • 4.2.1.2.5. Other Reagents
    • 4.2.1.3. Instruments
      • 4.2.1.3.1. Image Analysis Systems
      • 4.2.1.3.2. Microscopes
    • 4.2.1.4. Consumables and Accessories
  • 4.2.2. By Type
    • 4.2.2.1. Indirect Immunofluorescence
    • 4.2.2.2. Direct Immunofluorescence
  • 4.2.3. By Application
    • 4.2.3.1. Cancer
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Cardiovascular Diseases
    • 4.2.3.4. Autoimmune Diseases
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Academic and Research Institutes
    • 4.2.4.2. Pharmaceutical and Biotechnology Companies
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Hospitals and Diagnostic Centers
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Products
  • 4.3.2. By Type
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Immunofluorescence Assays Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Products
    • 5.2.1.1. Antibodies
      • 5.2.1.1.1. Primary Antibodies
      • 5.2.1.1.2. Secondary Antibodies
    • 5.2.1.2. Kits and Reagents
      • 5.2.1.2.1. Stains and Dyes
      • 5.2.1.2.2. Media and Sera
      • 5.2.1.2.3. Buffers and Solvents
      • 5.2.1.2.4. Probes
      • 5.2.1.2.5. Other Reagents
    • 5.2.1.3. Instruments
      • 5.2.1.3.1. Image Analysis Systems
      • 5.2.1.3.2. Microscopes
    • 5.2.1.4. Consumables and Accessories
  • 5.2.2. By Type
    • 5.2.2.1. Indirect Immunofluorescence
    • 5.2.2.2. Indirect Immunofluorescence
  • 5.2.3. By Application
    • 5.2.3.1. Cancer
    • 5.2.3.2. Infectious Diseases
    • 5.2.3.3. Cardiovascular Diseases
    • 5.2.3.4. Autoimmune Diseases
    • 5.2.3.5. Others
  • 5.2.4. By End-user
    • 5.2.4.1. Academic and Research Institutes
    • 5.2.4.2. Pharmaceutical and Biotechnology Companies
    • 5.2.4.3. Contract Research Organizations
    • 5.2.4.4. Hospitals and Diagnostic Centers
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Immunofluorescence Assays Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Products
        • 5.3.1.2.1.1. Antibodies
        • 5.3.1.2.1.1.1. Primary Antibodies
        • 5.3.1.2.1.1.2. Secondary Antibodies
        • 5.3.1.2.1.2. Kits and Reagents
        • 5.3.1.2.1.2.1. Stains and Dyes
        • 5.3.1.2.1.2.2. Media and Sera
        • 5.3.1.2.1.2.3. Buffers and Solvents
        • 5.3.1.2.1.2.4. Probes
        • 5.3.1.2.1.2.5. Other Reagents
        • 5.3.1.2.1.3. Instruments
        • 5.3.1.2.1.3.1. Image Analysis Systems
        • 5.3.1.2.1.3.2. Microscopes
        • 5.3.1.2.1.4. Consumables and Accessories
      • 5.3.1.2.2. By Type
        • 5.3.1.2.2.1. Indirect Immunofluorescence
        • 5.3.1.2.2.2. Indirect Immunofluorescence
      • 5.3.1.2.3. By Application
        • 5.3.1.2.3.1. Cancer
        • 5.3.1.2.3.2. Infectious Diseases
        • 5.3.1.2.3.3. Cardiovascular Diseases
        • 5.3.1.2.3.4. Autoimmune Diseases
        • 5.3.1.2.3.5. Others
      • 5.3.1.2.4. By End-user
        • 5.3.1.2.4.1. Academic and Research Institutes
        • 5.3.1.2.4.2. Pharmaceutical and Biotechnology Companies
        • 5.3.1.2.4.3. Contract Research Organizations
        • 5.3.1.2.4.4. Hospitals and Diagnostic Centers
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Immunofluorescence Assays Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Immunofluorescence Assays Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Immunofluorescence Assays Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Immunofluorescence Assays Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Thermo Fisher Scientific Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Bio-Rad Laboratories, Inc.
  • 20.3.3. Abcam plc
  • 20.3.4. PerkinElmer Inc.
  • 20.3.5. Merck KGaA
  • 20.3.6. Cell Signaling Technology, Inc.
  • 20.3.7. Medipan GmbH
  • 20.3.8. Sino Biological, Inc.
  • 20.3.9. Danaher Corporation
  • 20.3.10. EpigenTek Group Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer